Supernus Pharma (SUPN) Misses Q1 EPS by 13c

Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.34, $0.13 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $85.5 million versus the consensus estimate of $103.87 million.

Financial guidance reaffirmed

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Benchmark Reiterates Buy Rating on IMAX Corporation (IMAX), Highlights 'The Odyssey' Potential
• Hyperscale Data acquires 48.5 acres to expand Michigan campus